Ardent Health Partners, LLC (ARDT) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $9.42 (-0.84%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Ben Hendrix | RBC Capital | $13.00 | +38.0% |
| Dec 18, 2025 | Ann Hynes | Mizuho Securities | $12.00 | +27.4% |
| Nov 14, 2025 | Whit Mayo | Leerink Partners | $16.00 | +69.9% |
| Nov 14, 2025 | Ben Hendrix | RBC Capital | $16.00 | +69.9% |
| Oct 10, 2024 | Matthew Gillmor | KeyBanc | $24.00 | +154.8% |
| Sep 19, 2024 | Scott Fidel | Stephens | $24.00 | +154.8% |
| Aug 16, 2024 | Timothy Greaves | Loop Capital Markets | $21.00 | +122.9% |
| Aug 16, 2024 | David MacDonald | Truist Financial | $22.00 | +133.5% |
| Aug 12, 2024 | David MacDonald | Truist Financial | $21.00 | +122.9% |
| Aug 12, 2024 | Ann Hynes | Mizuho Securities | $20.00 | +112.3% |
| Aug 12, 2024 | Craig Hettenbach | Morgan Stanley | $27.00 | +186.6% |
Top Analysts Covering ARDT
ARDT vs Sector & Market
| Metric | ARDT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.17 | 2.24 | 2.40 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +37.9% | +11475.0% | +17.1% |
| P/E Ratio | 9.92 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6.55B | $6.57B | $6.61B | 8 |
| 2027-03-31 | $1.62B | $1.65B | $1.68B | 3 |
| 2027-06-30 | $1.70B | $1.73B | $1.76B | 3 |
| 2027-09-30 | $1.68B | $1.72B | $1.75B | 3 |
| 2027-12-31 | $1.73B | $1.76B | $1.79B | 3 |
| 2028-03-31 | $1.66B | $1.70B | $1.73B | 2 |
| 2028-06-30 | $1.76B | $1.80B | $1.83B | 2 |
| 2028-09-30 | $1.73B | $1.77B | $1.80B | 2 |
| 2028-12-31 | $1.78B | $1.82B | $1.85B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.03 | $1.14 | $1.37 | 6 |
| 2027-03-31 | $0.19 | $0.20 | $0.20 | 1 |
| 2027-06-30 | $0.39 | $0.40 | $0.41 | 1 |
| 2027-09-30 | $0.21 | $0.22 | $0.23 | 1 |
| 2027-12-31 | $0.39 | $0.40 | $0.41 | 1 |
| 2028-03-31 | $0.18 | $0.18 | $0.18 | 1 |
| 2028-06-30 | $0.41 | $0.42 | $0.43 | 1 |
| 2028-09-30 | $0.17 | $0.17 | $0.18 | 1 |
| 2028-12-31 | $0.38 | $0.39 | $0.39 | 1 |
Frequently Asked Questions
What is the analyst consensus for ARDT?
The consensus among 6 analysts covering Ardent Health Partners, LLC (ARDT) is Buy with an average price target of $13.33.
What is the highest price target for ARDT?
The highest price target for ARDT is $27.00, set by Craig Hettenbach at Morgan Stanley on 2024-08-12.
What is the lowest price target for ARDT?
The lowest price target for ARDT is $12.00, set by Ann Hynes at Mizuho Securities on 2025-12-18.
How many analysts cover ARDT?
6 analysts have issued ratings for Ardent Health Partners, LLC in the past 12 months.
Is ARDT a buy or sell right now?
Based on 6 analyst ratings, ARDT has a consensus rating of Buy (2.17/5) with a +37.9% upside to the consensus target of $13.33.
What are the earnings estimates for ARDT?
Analysts estimate ARDT will report EPS of $1.14 for the period ending 2026-12-31, with revenue estimated at $6.57B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.